EMA grants orphan drug designation to AB-201 for juvenile batten disease
Abeona Therapeutics, a biopharmaceutical company has granted orphan drug designation to the company’s novel candidate AB-201.
Release Date: 10-Jan-2017
Abeona Therapeutics, a biopharmaceutical company announced that European Medicines Agency (EMA) has granted orphan drug designation to the company’s novel candidate AB-201 to treat patients with Juvenile Batten Disease, a fatal lysosomal storage disease of the nervous system caused by autosomal-recessive mutations in the CLN3 gene.
The EMA’s designation of orphan status is granted to encourage new developments and therapies for rare diseases and disorders. Orphan status can be granted to those diseases that are rare. These incentives include protocol assistance, i.e. scientific advice specific for designated orphan medicines, and 10 years of market exclusivity once the medicine is on the market.
For Orphan Drug Clinical Insight Reports Contact: email@example.com
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.